Clinical expansion Praxis Medical has recently announced FDA clearance for the EndoCore EBUS-TBNA biopsy device, signaling regulatory validation and a potential gateway to expand into bronchoscopic biopsy workflows and hospital-based interventional suites.

Product differentiation The motorized, rotating fine needle biopsy devices (CytoCore & EndoCore) are positioned to collect more cellular tissue in fewer passes, offering a compelling value proposition for clinics aiming to improve diagnostic yield and reduce procedure time.

Targeted buyers With leadership led by an experienced interventional radiologist and a focus on physician-driven innovation, opportunities likely exist with interventional radiology, pulmonology, and pathology departments within mid-to-large hospitals and outpatient centers.

Market readiness Recent FDA clearance and a CGI of 1M–10M in revenue indicate a growing early-stage medical device company; push opportunities around pilot deployments, reimbursement navigation, and case studies to accelerate adoption in key clinical regions.

Strategic partnerships Consider collaborations with distributors, hospital GPOs, and training academies to scale adoption, plus digital marketing leveraging data from Google Analytics and search tools to identify high-intent clinics seeking improved biopsy outcomes.